2022 San Antonio Breast Cancer Symposium (SABCS 2022)

Trastuzumab deruxtecan confers hope as second-line therapy for HER2+ mBC

Roshini Claire Anthony, 20230120180001

Updated results of the DESTINY-Breast03 trial, presented at SABCS 2022, showed that in patients with HER2+ metastatic breast cancer, second-line treatment with trastuzumab deruxtecan conferred better survival benefits than treatment with trastuzumab emtansine.

Capivasertib + fulvestrant boosts PFS in AI-resistant HR+/HER2– advanced breast cancer

Roshini Claire Anthony, 20230108110001

The AKT inhibitor capivasertib, when added to fulvestrant, doubled progression-free survival (PFS) in patients with aromatase inhibitor (AI)-resistant hormone receptor-positive (HR+)/HER2*-negative (HER2–) advanced breast cancer (ABC), results of the phase III CAPItello-291 trial showed.

Can breast cancer survivors temporarily stop endocrine therapy to attempt pregnancy?

Roshini Claire Anthony, 20230105180001

Young breast cancer survivors could safely temporarily stop adjuvant endocrine therapy (ET) to attempt pregnancy, according to primary results of the POSITIVE* trial presented at SABCS 2022.

Updated monarchE results show improved treatment effects of abemaciclib for breast cancer

Audrey Abella, 20221228100000

In the preplanned overall survival (OS) interim analysis of the monarchE study, the combination of abemaciclib and endocrine therapy (ET) continued to provide benefit for individuals with HR+, HER2–, node-positive, high-risk early breast cancer even after completion of therapy.

EMERALD updates highlight therapeutic potential of elacestrant for ER+/HER2– mBC

Audrey Abella, 20221220100000

In the updated analysis of the phase III EMERALD trial, the next-generation oral SERD* elacestrant continued to show favourable signals for the treatment of ER+/HER2– metastatic breast cancer (mBC).